[Crizotinib for ROS1-rearranged non-small cell lung cancer patients]
Charlotte Domblides1, Martine Antoine2, Armelle Lavole1
1GH HUEP, AP-HP, hôpital Tenon, service de pneumologie, 4, rue de la Chine, 75970 Paris, France.
Abstract:
ROS1 fusions are rare mutations that preferentially concern young and non-smoker women. The ROS1-rearranged protein conserves an intact tyrosine kinase domain, leading to the constitutive activation of the ROS1 tyrosine kinase function and of its downstream pathways, that are known to be involved in tumorigenesis. These molecular abnormalities have shown their oncogenic potential in animals' models and in human, with an early effect on carcinogenesis. Several partners have been identified. Patients with non-small cell lung cancers (NSCLC) harbouring ROS1 alterations can receive specific targeted therapies. Indeed, crizotinib has recently been approved in France in advanced ROS1-rearranged NSCLC. We propose a review of the oncogenic role of ROS1 rearrangements, the different methods for its diagnosis, and the available treatments.
Insights
ROS1 fusions, rare in non-smokers, drive cancer by activating tyrosine kinase. Targeted therapies like crizotinib offer new treatment options for ROS1-rearranged non-small cell lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- ROS1 rearrangements are rare genetic alterations found in specific cancer types.
- These fusions lead to constitutive activation of ROS1 tyrosine kinase, promoting uncontrolled cell growth and tumorigenesis.
- The oncogenic role of ROS1 rearrangements has been established in preclinical and clinical settings.
Purpose of the Study:
- To review the oncogenic role of ROS1 rearrangements.
- To discuss diagnostic methods for identifying ROS1 alterations.
- To outline current and emerging treatment strategies for patients with ROS1-rearranged cancers.
Main Methods:
- Literature review of studies on ROS1 rearrangements.
- Analysis of preclinical data on ROS1-driven tumorigenesis.
- Review of clinical trial data for targeted therapies.
Main Results:
- ROS1 rearrangements activate downstream signaling pathways implicated in cancer development.
- Various fusion partners for ROS1 have been identified, influencing oncogenic activity.
- Targeted therapies, such as crizotinib, have demonstrated efficacy in patients with ROS1-rearranged non-small cell lung cancer (NSCLC).
Conclusions:
- ROS1 rearrangements represent a distinct molecular subtype of NSCLC with a clear oncogenic driver.
- Accurate diagnosis of ROS1 alterations is crucial for patient selection for targeted therapy.
- Crizotinib is an effective treatment option for advanced ROS1-rearranged NSCLC, highlighting the success of precision medicine.
More Related Videos
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers